By 2021, the 10 innovative pharmaceutical companies are expected to be listed on the Tablet

The effect of "planting eucalyptus trees and attracting golden phoenixes" is obvious.
2020, 27 biopharmaceutical (including CRO services) companies have successfully landed on the board, a 50% increase over 2019.
And the listing of biopharmaceuticals in 2020 has set milestones, such as the successful IPO of seven unprofitable Biotech companies, led by zeitgeist Pharmaceuticals, which was first listed under the "Fifth Set of Standards", after Regency Bio and Concino, which had previously been listed on the Hong Kong Stock Exchange, achieved a re-public offering of the Company's Board.
the opening of the Pharmaceutical Enterprises Science and Technology Board in 2020 will greatly ease the financing pressure of enterprises, thereby promoting their product development.
as 2020 drew to a close, we take stock of the innovative pharmaceutical companies that have a greater desire for an IPO in 2021 (the following public companies all use the "Standard 5" declaration) for your reference.
2021 is expected to be listed on the innovative pharmaceutical enterprise Baiji Shenzhou research and development pipeline, international symbols and founder resources in the industry can be said to be out of the right.
In the new round of health care negotiations, Baiji Shenzhou independently developed anti-PD-1 antibody for Reilly pearl monoantigen injection and BTK inhibitor Zebtini capsule a total of 4 approved adaptive disorders and with amgen strategic cooperation authorized by the deschu monoanti-anti-injection 1 approved adaptation is included in the national health insurance directory.
November 16, 2020, Baiji Shenzhou announced plans to list on the Shanghai Stock Exchange, and is expected to be completed in the first half of 2021.
the end of November, it was rumored that Baiji Shenzhou had signed a listing counseling agreement with COFCO and Goldman Sachs Gaohua Securities Co., Ltd. to officially start the listing of the board.
means that Baiji Shenzhou may become the first Chinese innovative biopharmaceutical company to list on NASDAQ, HKEx and Kotseng.
Dijsser Pharmaceuticals was established in October 2017 by a joint venture between China Investment Innovation and AstraZeneta, a multinational pharmaceutical company, to support Dr. Xiaolin Zhang, former head of AstraZenecom's Innovation Research and Development Center for Asia and Emerging Markets, and his team to start their own businesses.
August 2020, the company completed a $100 million round of A financing and established its China headquarters in Wuxi High-thr.
September 2020, Dizhe Pharmaceuticals began to receive guidance on the listing of Citic Securities.
Dizhe Pharmaceutical Products Pipeline Renren Biodeveloped Type 2 diabetes drug Yisheng Tai (Benaglutide Injection) was approved at the end of 2016 and went on sale in February 2017, with sales of 55.8808 million yuan in 2019, which is the company's main source of revenue.
this product in the new round of health care negotiations included in the health insurance list category B reimbursement products.
However, compared to other GLP-1, Benaglutide injection is given 3 times a day, 5 minutes before the meal subsurfic injection, the frequency of medication is higher, and need injection treatment, the patient's drug compliance or have a certain impact.
2020, renren bio-funding purposes Renren Bio announced that it will raise 3.005 billion yuan on the board, 40% of which will be used for new drug research and development projects.
the company's science and trot board application in July 2020 through the municipal committee meeting, is currently in the registration stage.
Bio-Olin Bio, a vaccine company based in Chengdu, has listed vaccines for sale, including the adsorption tejatric vaccine and the Hib-binding vaccine.
the company has yet to make a profit due to the promotional phase of its listed products, small revenues, and higher research and development spending and expenses.
the company on September 15, 2015 to list a new three boards, January 24, 2019 to terminate the listing of new three boards.
announced in June 2020 that it will raise $763 million for clinical research projects on vaccines, recombination of the golden staphylococcus vaccine, AC-Hib vaccine and pneumonia vaccine industrialization project.
Olin Biofunding Purposes As of November 17, Olin Bio has been questioned twice by the SSE, the most recent round of inquiries mainly related to hualan biology, Coen biological transactions and other matters.
The main product developed by Shanghai Yidi, Shanghai Yili, is also the only product is yew alcohol beam, which is a tumor chemotherapy drug, the new drug to be used in the first-line treatment of advanced non-small cell lung cancer is being reviewed by the Drug Review Center of the State Drug Administration.
In its prospectos, Shanghai Yidi expects the yew alcohol beam to be approved for listing in 2020, but the product received a CDE filing in November that requires companies to submit additional information and the time of listing is unknown.
it is worth mentioning that shanghai Kaibao, a listed company, is the second largest shareholder in Shanghai Yiyi with a 17.33 per cent stake.
Shanghai Friendship Fund-raising Purposes Shanghai Friends announced in August 2020 that it will raise 1.033 billion yuan in science and technology board, of which nearly 40% will be used for the annual output of 5 million injections of yew alcohol beam and supporting facilities.
as of December 25, the company had been questioned three times by the Shanghai Stock Exchange, the latest round of inquiries mainly related to the second shareholder Shanghai Kaibao whether to sign a gambling agreement and other matters.
, an innovative pharmaceutical company for antibody drug research and development and industrialization, has submitted the NDA to the FDA for its research and development of MIL60 (Beva Pearl Single Anti-Similar Drug).
days wide real product pipeline Tianguangshi is building 2 1000L stainless steel bioreactive reactor and its supporting purification production and preparation production line, with an annual production capacity of 350,000 preparations, is expected to be put into use in the first half of 2021;
days of wide-ranging fund-raising purposes Tianguang Shike's application was accepted on September 28, 2020, the company intends to raise 1.59 billion yuan, in November into the inquiry stage, the company has not disclosed the contents of its inquiries.
Jindik Jindik is a human vaccine company based in Taizhou, Jiangsu Province, which mainly includes 10 human vaccine products for the prevention of five adaptations, including influenza, rabies, chickenpox, shingles and pneumonia.
Jindik product pipeline Jindik developed the four-price influenza virus lysis vaccine was launched in November 2019, for the only domestic biological products 1 category 1 declared to CDE four-price influenza vaccine, in addition to its freeze-dried human rabies vaccine (Vero cells) in clinical Phase III trial stage.
26, 2020, Jindick's application for the Board was accepted and entered the inquiry phase in November.
as of December 22nd, Mr. Jindick had been questioned by Mr. Kcoff, which focused on core technology and its main business.
Mayway Bio's main business is including therapeutic monoclonal antibodies for human use, dual-specific/dual-functional antibodies and ADC drugs, as well as recombinant protein drugs. the
prospectine disclosed that 9MW0113 (Adamo monoantigen similar drug) developed in cooperation with Junshi Bio, a subsidiary of Meiwei Bio, had submitted an application for the listing of the new drug in November 2019, and that four other varieties in the study were in the critical registered clinical trial stage, of which 9MW0311 and 9MW0321 were in phase III clinical trials.
announced in December 2020 that it will raise 2.98 billion yuan in the board, mainly for the annual output of 1000 kg antibody industrialization construction projects and antibody drug research and development projects.
BioRebo Bio is a small nucleic acid drug development company based in Kunshan, Jiangsu Province, founded by Dr. Liang Zicai.
the company's research products cover ophthalmological diseases, tumors, infectious diseases, metabolic diseases, blood system diseases, cardiovascular diseases, rare diseases and other therapeutic areas.
December 29, 2020, the Shanghai Stock Exchange accepted the application for the listing of Therabo Biotech, which plans to raise 1.6 billion yuan, mainly for drug research and development projects (1,291 million yuan) and supplementary working capital (3.09 yuan).
Shengnoki Shengnoki is an innovative pharmaceutical company that started building a red-chip structure with VIE as early as 2006, and in May this year, the company created a board for sprint science, tearing down the red-chip structure that was built in 2009.
the company intends to raise 2,024 million yuan, mainly invested in new drug research and development projects for cancer and diabetes, chemical synthetic API SNG-1153 and SNG-1005 production and construction projects and operating and development reserve funds.
Sanoki's fund-raising application for Sanoki's Board was submitted for questioning in June 2020, although the company did not update its 2020 half-yearly report data in a timely manner until September 30, and its listing application is currently on hold.
In addition to the 10 pharmaceutical companies listed above, other companies such as Tianshili Bio, Jingyun Bio, Warner Pharmaceuticals, Chengda Bio, Sichuan Huiyu and other enterprises have also submitted their applications for listing to the Board, which is also expected to enter the capital market in 2021.
。